St. Jude Medical Announces Neuromodulation Division Name Change, Unveils New Brand Identity at 12th Annual North American Neuromodulation Society Meeting

St. Jude Medical, Inc. (NYSE:STJ) today announced that its neuromodulation division, formerly Advanced Neuromodulation Systems, has adopted the St. Jude Medical name. The St. Jude Medical Neuromodulation Division unveiled its new brand identity and showcased its flagship products – including the recently introduced Eon Mini™ neurostimulator – at the 12^th Annual North American Neuromodulation Society (NANS) Meeting, which begins today in Las Vegas.

St. Jude Medical, which acquired Advanced Neuromodulation Systems in 2005, is a market leader that develops, manufactures and markets implantable neuromodulation products with the goal of improving the quality of life for millions of people who suffer from disabling chronic pain and nervous system disorders.

"The neuromodulation division of St. Jude Medical has a rich history of innovation and excellence that began more than 25 years ago and continues to the present day,” said Chris Chavez, president of the St. Jude Medical Neuromodulation Division. "Our mission is to develop medical technologies and services that put more control into the hands of those who treat neurological and chronic pain patients worldwide. Ultimately, we have helped thousands of chronic pain patients realize that life can indeed get better.”

St. Jude Medical will showcase the following at NANS:

• A new corporate brand identity featuring the theme, "More Control. Less Risk.” The message reflects St. Jude Medical’s dedication to advancing the practice of medicine by focusing on reducing risk wherever possible and contributing to successful outcomes for every patient.
• The world’s smallest neurostimulator for chronic pain – Eon Mini – which was launched in September 2008.
• An expanded portfolio of products including EonC™, St. Jude Medical’s first extended life non-rechargeable neurostimulator, and Cinch™ anchor, an accessory designed to secure neurostimulation leads to mitigate lead migration.
• Fifteen poster and oral presentations representing research in areas such as deep brain stimulation for depression, peripheral field nerve stimulation for chronic pain, and spinal cord stimulation (SCS) for chronic pain of the back, arms and legs. These presentations reflect on the ongoing collaboration with physicians to develop new therapies for patients who have exhausted most other therapeutic options.

"St. Jude Medical has consistently demonstrated its commitment to the future of neuromodulation, and the benefits and relief it can offer patients suffering from chronic pain and other neurological disorders,” said Daniel J. Starks, chairman, president and chief executive officer of St. Jude Medical. ”Chronic pain is a growing problem worldwide, with one in five people suffering from this condition.”

While there is a large body of literature on the success of SCS, evidence continues to support its safety and effectiveness as a treatment for severe chronic pain. Published reports in Neurosurgery, Spine, The Journal of the American Medical Association and other publications indicate that SCS is more clinically effective than repeated back surgery and more cost effective. In a comprehensive review of more than 30 published studies, findings confirm the effectiveness of SCS as an early treatment option for failed back surgery syndrome patients.

In the United Kingdom earlier this fall, the National Institute for Health and Clinical Excellence (NICE) recommended that spinal cord stimulation be made available to all patients who continue to experience chronic neuropathic pain for at least six months despite trying conventional approaches to pain management. To review the NICE guidance, please visit www.nice.org.uk/Guidance/TA159.

St. Jude Medical is developing new technologies to address a growing list of neurological disorders. Clinical studies are currently underway for Parkinson’s disease, essential tremor, migraine headaches and major depressive disorder among others. In addition, St. Jude Medical continues to support educational outreach efforts through such organizations as the National Pain Foundation (www.nationalpainfoundation.org), American Society of Interventional Pain Physicians (www.asipp.org), the Neuromodulation Therapy Access Coalition (www.neuromodulationaccess.org) and others.

More than 45,000 patients in 35 countries have been implanted with St. Jude Medical neurostimulation systems. Patients can obtain more information about neurostimulation pain therapies at www.PowerOverYourPain.com.

About St. Jude Medical

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. Headquartered in St. Paul, Minn., St. Jude Medical employs more than 13,000 people worldwide and has five major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiac surgery, cardiology and neuromodulation. For more information, please visit www.sjm.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2007 and Quarterly Report on Form 10-Q for the fiscal quarter ended September 27, 2008. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.